Inventor
Bernard Thomas Golding
Inventor
Newcastle upon Tyne, GB
Overview
Patents· 28 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds34%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations33%
A61KPreparations for medical, dental or toiletry purposes18%
C07CAcyclic or carbocyclic compounds5%
C07BGeneral methods of organic chemistry4%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium4%
C07HSugars2%
PatentTitleYear
10,981,898Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity202110,544,132Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity202010,526,311Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity202010,414,726Therapeutic agents201910,344,017Pyrrolcarboxamide derivatives for the inhibition of ERK520199,358,222'Therapeutic agents'20168,618,158'Therapeutic agents'20138,530,651'Process for the preparation of anagrelide and analogues'20138,304,420'Substituted quinazolines for reducing platelet count'20128,258,175'Isoindolin-1-one derivatives'20127,910,597'Substituted quinazolines'20117,732,483'DNA-PK inhibitors'20107,696,203'DNA-PK inhibitors'20107,674,823'DNA-PK inhibitors'20107,402,607'DNA-PK inhibitors'20087,226,918'DNA-PK inhibitors'20077,105,518'Thiopyrane-4-ones as DNA protein kinase inhibitors'20066,677,345'Cyclin dependent kinase inhibitors'20046,316,455'Method of improving the effectiveness of a cytotoxic drug or radiotherapy using a quinazolinone compound'20016,310,082'Benzimidazole compounds'20016,303,618'Cyclin dependent kinase inhibiting purine derivatives'20016,297,250'Pyrimidopyrimidine compounds'20016,258,840'Analogues or derivatives of quercetin (prodrugs)'20016,156,739'Quinazolinone compounds'20006,100,283'Benzimidazole compounds'20006,015,827'Benzoxazole-4-carboxamides and their use in inhibiting poly (adp-ribose) polymerase activity and improving cytotoxic effectiveness of cytotoxic drugs or radiotherapy'20005,985,913'Tetracyclic compounds for enhancing biosynthesis of erythropoietin, compositions containing same, and methods of use thereof'19995,756,510'Benzamide analogs useful as PARP (ADP-ribosyltransferase, ADPRT) DNA repair enzyme inhibitors'1998Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1998–2001Patents assigned to UNIV NEWCASTLE VENTURES LTD (7)· patent assignee history
1998–2021Based in Newcastle upon Tyne, GB· patent location history
2006–2016Patents assigned to CANCER REC TECH LTD (9)· patent assignee history
2008–2010Patents assigned to KUDOS PHARM LTD (3)· patent assignee history
2016Based in Shiremoor, GB· patent location history
2019–2021Patents assigned to CANCER RESEARCH TECH LTD (5)· patent assignee history
2020–2021Patents assigned to ASTEX THERAPEUTICS LTD (3)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| CANCER REC TECH LTD | 9 | 2006–2016 |
| UNIV NEWCASTLE VENTURES LTD | 7 | 1998–2001 |
| CANCER RESEARCH TECH LTD | 5 | 2019–2021 |
| ASTEX THERAPEUTICS LTD | 3 | 2020–2021 |
| KUDOS PHARM LTD | 3 | 2008–2010 |
Locations
| Location | Patents | Span |
|---|---|---|
| Newcastle upon Tyne, GB | 27 | 1998–2021 |
| Shiremoor, GB | 1 | 2016 |